The current status of enteric fever diagnostics and implications for disease control by Baker, S. et al.
This is a repository copy of The current status of enteric fever diagnostics and implications
for disease control.
White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/164507/
Version: Published Version
Article:
Baker, S., Blohmke, C.J., Maes, M. et al. (2 more authors) (2020) The current status of 
enteric fever diagnostics and implications for disease control. Clinical Infectious Diseases, 
71 (Supplement_2). S64-S70. ISSN 1058-4838 
https://doi.org/10.1093/cid/ciaa503
eprints@whiterose.ac.uk
https://eprints.whiterose.ac.uk/
Reuse 
This article is distributed under the terms of the Creative Commons Attribution (CC BY) licence. This licence 
allows you to distribute, remix, tweak, and build upon the work, even commercially, as long as you credit the 
authors for the original work. More information and the full terms of the licence here: 
https://creativecommons.org/licenses/ 
Takedown 
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by 
emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. 
S U P P L E M E N T  A R T I C L E
S64 • CID 2020:71 (Suppl 2) • Baker et al
Clinical Infectious Diseases
 
Correspondence: T.  C. Darton, Florey Advanced Clinical Fellow, Florey Institute for Host-
Pathogen Interactions, Department for Infection, Immunity and Cardiovascular Disease, Faculty 
of Medicine, Dentistry and Health, University of Shefield, Shefield S10 2RX, UK (t.darton@
shefield.ac.uk).
Clinical Infectious Diseases®  2020;71(S2):S64–70
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society 
of America. This is an Open Access article distributed under the terms of the Creative Commons 
Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted 
reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
DOI: 10.1093/cid/ciaa503
he Current Status of Enteric Fever Diagnostics and 
Implications for Disease Control
Stephen Baker,1 Christoph J. Blohmke,2 Mailis Maes,1 Peter I. Johnston,3 and Thomas C. Darton3
1Cambridge Institute of Therapeutic Immunology and Infectious Disease, Department of Medicine, University of Cambridge, Cambridge, United Kingdom, 2Data Science and Clinical Systems, GSK 
Vaccines, Siena, Italy, and 3Florey Institute for Host-Pathogen Interactions, Department for Infection, Immunity and Cardiovascular Disease, Faculty of Medicine, Dentistry and Health, University of 
Shefield, Shefield, United Kingdom
Enteric (typhoid) fever remains a problem in low- and middle-income countries that lack the infrastructure to maintain sanitation 
and where inadequate diagnostic methods have restricted our ability to identify and control the disease more efectively. As we move 
into a period of potential disease elimination through the introduction of typhoid conjugate vaccine (TCV), we again need to re-
consider the role of typhoid diagnostics in how they can aid in facilitating disease control. Recent technological advances, including 
serology, transcriptomics, and metabolomics, have provided new insights into how we can detect signatures of invasive Salmonella 
organisms interacting with the host during infection. Many of these new techniques exhibit potential that could be further ex-
plored with the aim of creating a new enteric fever diagnostic to work in conjunction with TCV. We need a sustained efort within 
the enteric fever ield to accelerate, validate, and ultimately introduce 1 (or more) of these methods to facilitate the disease control 
initiative. he window of opportunity is still open, but we need to recognize the need for communication with other research areas 
and commercial organizations to assist in the progression of these diagnostic approaches. he elimination of enteric fever is now be-
coming a real possibility, but new diagnostics need to be part of the equation and factored into future calculations for disease control.
Keywords.  enteric fever; typhoid; diagnostics; Salmonella; global health.
Enteric (typhoid) fever is a clinical syndrome caused by inges-
tion of the gram-negative bacteria Salmonella enterica serovar 
Typhi (S. Typhi) or Salmonella enterica serovar Paratyphi (S. 
Paratyphi) A, B, or C.  Despite the availability of good anti-
microbial treatment regimens and new-generation conjugate 
vaccines for preventing S. Typhi infection (TCVs), enteric fever 
continues to cause a significant degree of morbidity and mor-
tality worldwide; current estimates suggest approximately 13.5–
26.9 million new cases of S. Typhi and S. Paratyphi A (the focus 
of this review) each year [1, 2]. The uncertainty around these 
estimates is, in part, due to the limitations in availability and 
performance of current diagnostic tools.
Enteric fever is associated with a broad spectrum of clin-
ical disease, ranging from asymptomatic to severe symptoms, 
such as fever, malaise, headache, and complications of ileal 
ulceration including perforation and profuse hemorrhage. 
Furthermore, some individuals who are exposed to S. Typhi or 
S. Paratyphi A will go on to become long-term carriers, where 
the organisms are retained in the gallbladder and occasionally 
at other sites including the kidney. Why diferent individuals 
present with difering clinical symptoms is not understood, 
but laboratory models and human challenge with virulent or-
ganisms have revealed a highly complex natural history of 
infection resulting from the co-evolution of bacteria with hu-
mans. he result is that both S. Typhi and S. Paratyphi A are 
exquisitely adapted to transit almost efortlessly throughout the 
human body, triggering a cascade of events that result in symp-
tomatic disease in some, and long-term asymptomatic car-
riage in others. Consequently, diagnosing enteric fever remains 
an enigma, with symptomatic infections mimicking various 
aspects of many other infectious diseases. hese factors are es-
pecially relevant in settings with the limited resources found in 
low- and middle-income countries (LMICs), where diferential 
diagnostic tests (many of which have their own inherent limi-
tations) for febrile disease are oten not available, and diagnosis 
is performed purely on the clinical judgment of an attending 
healthcare worker [3].
Inaccurate diagnosis of enteric fever (and other common 
febrile diseases) results in the under- or overdiagnosing of in-
fectious pathologies and frequently unsuitable treatment. he 
knock-on efects of inaccurate diagnosis include inappropriate 
antimicrobial prescribing and suboptimal clinical management, 
which may contribute to the development and preservation of 
antimicrobial resistance. Additionally, a lack of a reliable diag-
nostic results in public health policymakers being supplied with 
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poor-quality data, posing challenges to the efective evaluation 
or introduction of new interventions, including potentially ef-
fective vaccination strategies [3–5].
Almost all techniques for diagnosing an infectious disease 
focus on (1) the direct detection of the pathogen of interest (either 
the entire pathogen through culture or a fragment of it through 
a molecular process), or (2), the indirect detection of the path-
ogen via a measurement derived from the host response to the 
infecting agent, indicating recent exposure or active infection. 
he development of new rapid diagnostics for enteric fever has 
been a challenge for decades, with blood culture remaining the 
only real widely used standard against which new tests and inter-
vention strategies are evaluated. he performance of blood culture 
in detecting S. Typhi/S. Paratyphi A varies markedly and requires 
automated culture systems and an adequate volume of blood to 
be most efective [4]. Even in highly controlled experimental set-
tings, the sensitivity of automated blood culture may only reach 
80% [6]. A recent meta-analysis measured a diagnostic sensitivity 
of 59% (95% conidence interval, 54%–64%), when compared to 
the seldom used, true gold standard of bone marrow aspirate cul-
ture [7]. Various eforts have been made to improve the accuracy 
of the standard against which to perform diagnostic evaluations, 
including the use of composite endpoints or Bayesian latent class 
modeling analysis [8–10].
In parallel to new research methods, there has been a resur-
gence of interest in exploring new approaches to identifying 
the cause of fever in patients in LMICs. he ready availability 
of access to blood and/or serum in patients may facilitate the 
application of novel high-throughput methods. hese methods 
remain largely agnostic, aiming to identify disease-speciic sig-
natures or biomarkers indicating recent or active infection, and 
are principally conducted as a component of a comprehensive 
research program, not least due to the bulk of information ac-
quired with the attendant requirement for computing and bio-
informatic processing ability. he overall aim of such programs 
is to exploit such datasets to obtain highly detailed and individu-
alized data not available through previous studies, and is only 
possible now due to access to, and decreasing costs of, many 
high-throughput molecular technologies. Parallel advances are 
required in biological annotation, mathematical modeling, and 
computational analysis techniques that will lead to an unprece-
dented array of approaches in which to interrogate the large and 
complex datasets that are generated. Here, we describe several 
such new and innovative approaches for the identiication and 
early validation of acute enteric fever through transcriptomics, 
metabolite proiling, and the humoral response to the organ-
isms. We discuss these new techniques and their pros and cons 
as we move into a new era of typhoid control and elimination.
SEROLOGICAL RESPONSES
The detection of an antibody response indicating recent infec-
tion or exposure using an easily accessible and standardized 
biological sample substrate (such as serum or plasma) remains 
an attractive approach for enteric fever diagnostics. The hypo-
thetical advantages to serological methods include avoiding 
the infrastructure (including reagents, equipment, and labora-
tory capacity) and training required to perform culture-based 
diagnostics as well as the potential rapidity of such methods. 
Realistically, at the time of writing, if we are to have a new uni-
versal point-of-care diagnostic test for enteric fever within the 
next 5 years, it will likely be based on a serological assay via a 
lateral flow platform. The ease of use of lateral flow systems, the 
ability to combine the reagents for an enteric fever assay with 
tests for other fever-causing pathogens, and the amount of data 
that can be obtained from a small volume of easily accessed 
biological sample currently make serology the most likely 
short-term solution. Technologies exist to move into this area 
now, but we still lack suitable, reproducible serological targets. 
While several advances have been made over the poorly per-
forming Widal test, which has now been in use for > 100 years, 
these have largely been minor incremental gains, resulting in 
a new generation of serological diagnostic tests that still pro-
duce unacceptable levels of specificity and sensitivity for clin-
ical and epidemiological use. Several remaining limitations of 
these serological diagnostics stem from the narrow repertoire 
of antigen/antibody combinations (targets) that are unique to S. 
Typhi/S. Paratyphi [11] and their downstream suboptimal eval-
uation and reporting in appropriate populations or clinical 
studies [12].
he problem faced by researchers in determining which 
target(s) to use for new serological tests for enteric fever is dem-
onstrated by human challenge study data from nonendemic 
settings [6]. In the Oxford challenge model, healthy adult vo-
lunteers ingest a single dose of the challenge organism (S. Typhi 
Quailes strain) and are closely monitored over 14 days for di-
sease and recovery. he collection of serum samples at multiple 
time points before and ater challenge followed by probing with 
a panel of approximately 4500 Salmonella antigens demon-
strated the broad and highly heterogenous antibody response to 
S. Typhi exposure and infection [13]. he response to Salmonella 
infections in endemic populations is potentially ampliied by 
prior exposure occurring throughout childhood, but it remains 
highly complex and equally diicult to disaggregate.
To navigate the limitations of trying to identify the most indic-
ative antigen/antibody combinations, several groups have used 
protein microarray platforms to down-select targets in both en-
demic and nonendemic populations, with subsequent explora-
tion and validation by standard enzyme-linked immunosorbent 
assay and other approaches designed to detect antigen-speciic 
antibody [14]. he most promising targets identiied through 
these approaches and the populations in whom these have 
been further explored and validated include immunoglobulin 
G (IgG) and immunoglobulin A (IgA) responses to hemolysin 
E and S. Typhi–speciic lipopolysaccharide (LPS) in pediatric 
D
o
w
n
lo
a
d
e
d
 fro
m
 h
ttp
s
://a
c
a
d
e
m
ic
.o
u
p
.c
o
m
/c
id
/a
rtic
le
/7
1
/S
u
p
p
le
m
e
n
t_
2
/S
6
4
/5
8
7
7
8
1
7
 b
y
 U
n
iv
e
rs
ity
 o
f S
h
e
ffie
ld
 u
s
e
r o
n
 1
7
 A
u
g
u
s
t 2
0
2
0
S66 • CID 2020:71 (Suppl 2) • Baker et al
cases in Nigeria [14], immunoglobulin M and/or IgG responses 
to hemolysin E, the cdtB protein (a component of typhoid toxin) 
in patients with enteric fever in Bangladesh [15], and IgA re-
sponses to S. Typhi–speciic LPS and cell invasion protein sipC 
and IgG against hemolysin E in the Oxford human challenge 
study [13]. he targets identiied in these latter studies went on 
to be validated in patients with natural infection in Nepal [13]. 
A remaining issue with use of individual antigen targets is the 
potential for cross-reactivity with other commensal or patho-
genic organisms.
he key take-home messages from these studies is that se-
rological tests to diagnose enteric fever are feasible but not as 
straightforward as predicted and that such approaches are likely 
to be even more challenging to validate convincingly in endemic 
patient populations. he major limitations to routine clinical 
use include the current need for follow-up sampling, unless 
unequivocal population standard titers for comparison can be 
demonstrated, and the current inability to infer antimicrobial 
susceptibility to guide treatment in the era of increasing anti-
microbial resistance. Recent studies employing unbiased anal-
ysis for candidate antigen/antibody selection have revealed a 
possible route toward a point-of-care serological test for en-
teric fever, in particular through the use of combination panels 
incorporating multiple antigen targets with both polysaccharide 
and protein antigens, and the ability to detect multiple antibody 
isotypes. hese approaches seem to increase the sensitivity and 
speciicity, decrease the potential efects of the heterogeneity in 
antibody response, and provide some indication into how re-
cently the infection occurred, thus preventing the requirement 
for additional samples taken at multiple time points.
TRANSCRIPTOMICS
Transcriptomics (functional genomics) is the systematic meas-
urement of gene expression at a specific time point in a given 
cellular compartment. The quantity of each transcript is meas-
ured by calculating the amount of messenger RNA transcribed 
from genomic DNA (ie, gene expression) using any one of a 
number of high-throughput molecular technologies, such as 
microarrays and RNAseq. Transcriptomic profiles generally 
consist of thousands of individual quantitative data points pro-
viding a high-resolution, cross-sectional snapshot of the host 
response to a given stimulus such as infection or vaccination. By 
annotating genes with biological functions, and incorporating 
them into common pathways, these profiles can be used as a 
proxy for interpreting the broad response state of the cell com-
munity in that compartment, such as within polymorphonu-
clear cells in peripheral blood. Patently, cell-specific signatures 
may be difficult to disaggregate given the mixed populations 
of cell types that may be represented in the assayed sample. 
Profiles can be generated from a comparatively small quan-
tity of biological sample (eg, whole blood) [16]. Consequently, 
transcriptomic science has evolved in recent years and been 
exploited to generate detailed insights into the human tran-
scriptional response to numerous infectious diseases [17–22] 
and other alternative immune perturbations [23–26]. These 
studies produce a fairly standardized output and generate large 
amounts of data, which are available through public repositories 
(eg, GEO or ArrayExpress), making them readily accessible for 
detailed downstream cross-study analysis.
he wealth of available data in transcriptomics studies pro-
vides a unique opportunity for identifying diagnostic signatures 
and, when combined, these datasets are more than suicient to 
apply advanced analysis algorithms, such as supervised learning 
approaches, to identify transcriptional patterns that are speciic 
to any given infection or disease state [27]. Such potential was 
demonstrated elegantly by Herberg et al [28]; this group gen-
erated a large dataset by combining transcriptional proiles in 
publicly available databases generated from febrile children in 
Europe and North America. he authors identiied a reproduc-
ible transcriptional signature able to distinguish viral from bac-
terial infections in these febrile children. his study performed 
logistic regression using an elastic net algorithm in combination 
with a forward-selection partial least square feature selection 
approach, yielding a 2-gene signature (FAM89A and IFI44L) 
able to distinguish bacterial from viral causes of febrile illness 
with high accuracy [28, 29].
he Oxford human challenge model has been the source of 
several large gene expression datasets, which were generated 
in a highly controlled setting, permitting the interrogation of 
the human transcriptional responses to infection with both S. 
Typhi and S. Paratyphi A [21, 22, 30]. More recently, we were 
able to augment these data with transcriptional data from blood 
culture–conirmed enteric fever cases in Nepal to generate a 
unique dataset using the standardized laboratory methods [31]. 
In this proof-of-concept study, this dataset was amalgamated 
with transcriptional proiles generated from blood taken from 
individuals sufering from uncomplicated dengue fever, blood-
stage malaria infection with Plasmodium falciparum, and ac-
tive pulmonary tuberculosis. Using a random forest algorithm 
with integrated feature selection, we identiied 5 genes (STAT1, 
SLAMF8, PSME2, WARS, and ALDH1A1) that were able to dis-
tinguish culture-conirmed enteric fever cases from the other 
infections with > 96% accuracy in an independent validation 
cohort. While the infections chosen as comparators may not be 
universally optimal in enteric fever–endemic settings, these data 
outline 3 important points. First, this study provides evidence 
that the host response is a feasible source of biomarkers that 
are robustly speciic to identify enteric fever patients. his ob-
servation contrasts the traditional and more intuitive approach 
to diagnostic biomarker discovery for infections, where the test 
aims to directly detect the pathogen of interest via culture, pol-
ymerase chain reaction (PCR) ampliication, or antigen detec-
tion. Second, this study further conirms that gene expression 
proiles are speciic enough to potentially distinguish diseases 
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with similar clinical presentation, such as undiferentiated fever 
syndromes [32]. hird, this approach could lend itself to the 
detection of multiple diferent infections. here may be limited 
commercial value in developing a test to identify an infection 
caused by 1 pathogen, and the ability to combine multiple tar-
gets with suitable speciicity realistically appears more reliable 
and clinically advantageous.
he studies distinguishing bacterial and viral infections, 
and the enteric fever investigation described here, highlight 
that a combination of high-resolution human transcriptional 
response data (generated from human samples using high-
throughput technologies) with advanced analytics, including 
machine learning methods, are powerful tools to identify novel 
diagnostic biomarkers for infectious diseases and may represent 
the future of molecular diagnostics for enteric fever.
METABOLOMICS
Metabolomics is a comparatively new area of scientific research, 
which has evolved with our ability to detect and measure mi-
nute quantities of small chemicals in complex biological ma-
terial using cutting-edge mass spectrometry technologies [33]. 
Through the detailed analysis of biological material, metab-
olomics provides holistic overview of the metabolites (small 
molecules that are intermediates and downstream products 
of metabolic pathways) held in the analyzed compartment. 
In contrast to transcriptomics, which only measures relative 
transcription, metabolic profiling provides an insight into the 
direct chemical physiology within the sample and a greater 
understanding of biological processes in action. In diagnostic 
application, metabolomics provides chemical signatures that 
arise through cellular processes subverted through the disease 
process. Cellular processes act in equilibrium; therefore, when 
a pathogen interacts with the host and the host produces a 
cellular response, such as inflammation or initiation of adap-
tive immune mechanisms, this equilibrium may be impacted. 
Additionally, infecting organisms activate their own specific 
cellular pathways to induce infection resulting in the potential 
modification of downstream metabolites. Metabolomics aims 
to detect these subtle changes in cellular processes and, unlike 
serology and transcriptomics, may be able to provide both di-
rect and indirect evidence of the pathogen being present and of 
its impact on the host.
Metabolomics has been applied to various infectious dis-
eases and sample types, identifying signatures of urinary tract 
infections in urine, inlammatory disease in cerebrospinal luid, 
and viral infections in serum samples [34–36]. Furthermore, 
the technique may also be able to predict disease outcomes, 
progression, and even disease onset, as was recently reported 
for tuberculosis [37]. Given the inherent issues with the diag-
nosis of enteric fever, metabolomics may ofer an alternative 
approach by providing an exceptionally high-resolution snap-
shot of a patient presenting with a fever of unknown origin. We 
were able to exploit this technique to generate metabolite sig-
natures on plasma samples by 2-dimensional gas chromatog-
raphy with time-of-light mass spectrometry from 50 patients 
with enteric fever (25 with S. Typhi and 25 with S. Paratyphi 
A) against 25 afebrile controls [38]. An extension orthogonal 
partial least squares with discriminant analysis model was itted 
to diferentiate the various groups and 306, 324, and 58 metab-
olite peaks were found to signiicantly separate controls from 
the S. Typhi infections, controls from the S. Paratyphi A infec-
tions, and the S. Typhi infections from S. Paratyphi A  infec-
tions, respectively. Notably, the potential of this technique was 
highlighted by the ability to separate infections caused by the 2 
serovars by a collection of speciic chemicals, which included 
phenylalanine, pipecolic acid, and 2-phenyl-2-hydroxybutanoic 
acid. Furthermore, a metabolite proile comprising 6 classiied 
metabolites (ethanolamine, gluconic acid, monosaccharide, 
phenylalanine, pipecolic acid, and saccharide) had high dis-
criminatory ability for all enteric fever patients, at least in this 
set of Nepali patients. his study was later replicated in patient 
samples from Africa and an additional cohort of patients in Asia 
[39]. he principal message from this secondary study was that 
at least 24 metabolites can identify enteric fever (S. Typhi only 
in the secondary study), and included the biologically plausible 
chemicals, glycerol-3-phosphate (carbon source and precursor 
for phospholipid biosynthesis), stearic acid (component of lip-
osome), and linoleic acid (bactericidal activity), pyruvic acid, 
and creatinine. Last, by employing these techniques (sample 
processing, chemical analysis, and mathematical modeling), we 
were additionally able to disaggregate S. Typhi and S. Paratyphi 
A carriers from the proiles generated from the plasma of the 
noncarriers [40].
he limited available data suggest that metabolite proiles are 
a potential future solution for diagnosing enteric fever, but there 
are many challenges in making these indicative chemical sig-
natures routinely accessible in LMICs. First, there needs to be 
expansion of available data for enteric fever and validation of 
current hits in difering laboratories. his primary step is un-
derway as a function of the Strategic Typhoid alliance across 
Africa and Asia study (STRATAA) study, which is being con-
ducted in Nepal, Bangladesh, and Malawi. As described in the 
STRATAA protocol, plasma and urine samples from blood 
culture–conirmed enteric fever patients will be processed to 
validate the preliminary chemical hits and for additional ex-
ploration [41]. Second, the already available hits need to be 
studied and simple assays need to developed that can detect 
and quantify these small chemicals in plasma. his secondary 
step requires the input of chemists and organizations that have 
the proven experience of developing new technologies for di-
agnostic tests. hird, metabolite proiling arguably provides 
the most “revolutionary” approach over other new diagnostic 
techniques and could easily be scaled up to incorporate other 
disease etiologies and pathologies. For this approach to work, 
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there needs to be substantial investment in metabolite proiling 
of multiple diferent infections and the development of diag-
nostic chemical panels and a platform on which they can be 
measured. his standardization seems unlikely at present, but 
the development of clinically accessible mass spectrometry 
tools such as matrix-assisted laser desorption/ionization–time 
of light technology has revolutionized bacterial identiication 
in clinical microbiology laboratories in less than a decade. he 
development of a standard approach that can diagnose any in-
fection would be the long-term aspiration of every infectious 
disease clinician, and metabolomic proiling may be a suitable 
methodology for which to challenge this aim.
OTHER DIAGNOSTIC APPROACHES
While there is some interest in the technical challenge of de-
veloping better diagnostic tools for enteric fever, the question 
remains as to whether these can improve over clinical acumen 
alone. As a syndrome, the symptoms of enteric fever are non-
specific with a wide differential diagnosis. Certain features, 
such as rose spots, relative bradycardia, and “typhoid tongue,” 
may be indicative, but their presence is far from universal [42]. 
Outbreaks of enteric fever in the United States in the 1980s re-
ported varying rates of rose spots (5%–30%) [43]. In Turkey, an 
attempt was made to develop a prediction model for typhoid 
from a cohort of patients presenting persistent fever, using cul-
ture of S. Typhi from stool, blood, bone marrow, or urine plus 
a consistent clinical presentation as diagnostic, and contrasting 
with febrile patients who did not meet the case criteria [44]. Age 
(< 30 years), abdominal distention, confusion, leukopenia, rela-
tive bradycardia, a positive Widal test, and typhoid tongue were 
included in the final prediction model. The presence of 4 or 
more of these features was associated with a sensitivity of > 85% 
and specificity of > 78%. Unfortunately, the proportion of par-
ticipants with this number of features was not reported, but it 
is improbable that many “real-world” patients would possess 
these features.
In reality, community and hospital clinics in low-resource 
tropical settings are inundated with patients presenting with 
undiferentiated febrile illness every day. he number of these 
cases peaks in the monsoon or “green” season and, while the ma-
jority of patients may be children or younger adults, many may 
also have underlying medical comorbidities or socioeconomic 
risk factors such that a wide range of diferential clinical diag-
noses needs to be taken into account, of which only one will be 
enteric fever. While parallel surveillance programs may provide 
support with identifying common prevailing causes of fever and 
some susceptibility data to guide therapeutic selections, these 
are expensive to maintain or a result of external inluence, in-
cluding research studies, vaccine introduction surveillance, or 
enhanced vigilance surrounding an outbreak. In these settings, 
rapid and afordable, multipathogen point-of-care tests could 
play a major role in individual patient management and disease 
control but could also alleviate considerable healthcare strain in 
coping with this patient load.
Aside from newer technologies, several other laboratory 
techniques remain the focus of research toward developing 
better enteric fever diagnostics, including molecular detection 
of bacterial genes using PCR. PCR techniques are the current 
mainstay of infectious disease molecular- and non-culture-
based diagnostics and, in the case of enteric fever, are fre-
quently designed to detect the lagellin genes of S. Typhi and S. 
Paratyphi A, or other more speciic targets [45, 46]. he attrac-
tion of PCR-based approaches includes the ability to detect bac-
terial nucleic acid, which does not depend on recovery of living 
organism and therefore remains theoretically advantageous, 
especially in settings where antimicrobial use in the commu-
nity is high. However, any pathogen-directed test for S. Typhi/S. 
Paratyphi A remains restricted by the low concentration of bac-
teria in the peripheral blood and perhaps inherent inhibitors 
in the biological sample of choice [47]. Techniques to lyse red 
blood cells have shown some promise in increasing yield [48], 
and removing human DNA from samples may produce an ad-
ditional yield, thereby further improving sensitivity and speci-
icity by reducing competing targets [49].
Loop-mediated isothermal ampliication (LAMP) is a tech-
nique that permits the ampliication of nucleic acid at a con-
stant temperature, removing the need for thermal cyclers and 
a permanent electricity supply. LAMP targeting a speciic S. 
Typhi gene produced a positive signal for all positive blood 
cultures and no (or few, depending on the primers used) false 
positives in a clinical evaluation [50, 51]. he sensitivity of 
the technique was < 40% (again, primer dependent) when 
performed on peripheral blood samples taken from the same 
patients [51]. Quantitative PCR, using an existing and more 
standardized approach on the same samples, performed sim-
ilarly. he technique may give more immediate results than 
blood culture, but does not improve sensitivity and is severely 
limited by restricting the assay to detect individual pathogens 
targets.
While multiple studies have assessed PCR-based approaches, 
frequent limitations include methodological issues that cannot 
exclude contamination, study design that fails to include sui-
cient reference standard samples, or absence of direct testing of 
clinical material. Studies in which high sensitivities have been 
reported should remain guarded for these described limita-
tions. In summary, no standardized PCR technique exists, and 
procedures to optimize sensitivity add expense and complica-
tion to an already costly procedure. Such limitations, and the 
fact that the concentration of nucleic acid in the blood is oten 
below a detectable yield, makes PCR in its current format un-
suitable for use in endemic settings where enteric fever tests 
need to have the greatest sensitivity and speciicity.
D
o
w
n
lo
a
d
e
d
 fro
m
 h
ttp
s
://a
c
a
d
e
m
ic
.o
u
p
.c
o
m
/c
id
/a
rtic
le
/7
1
/S
u
p
p
le
m
e
n
t_
2
/S
6
4
/5
8
7
7
8
1
7
 b
y
 U
n
iv
e
rs
ity
 o
f S
h
e
ffie
ld
 u
s
e
r o
n
 1
7
 A
u
g
u
s
t 2
0
2
0
Typhoid Diagnostics • CID 2020:71 (Suppl 2) • S69
OUTLOOK
The field of clinical diagnostics is rapidly evolving and newer 
technologies, analytical advances, and funder interests are 
having a major impact in driving their application to the study, 
management, and control of human and veterinary diseases. 
Diagnostics for infectious diseases have also moved forward, but 
arguably not at the same rate as in the areas of oncology, cardi-
ology, and metabolic disease. New bacteriological methods and 
molecular approaches are slowly being introduced into clin-
ical microbiology laboratories in higher-income countries, but 
many of these techniques are not directly transferable to LMIC 
settings with fewer resources. Realistically, outside of major 
surveillance studies and vaccine implementation programs, we 
are no better at routinely diagnosing or measuring typhoid in-
cidence than we were 25  years ago. The reasons for this dis-
appointing reality are multifaceted and associated with the 
biological and technical complexity of the challenge, the lack 
of a harmonized response (including coordination between 
different investigators and geographical areas, between investi-
gators, funders, and biotechnological companies, and between 
different disease control modalities, specifically treatment and 
prevention measures), poor study design, a focus on other pri-
orities in the enteric fever field (ie, TCV licensure and intro-
duction), and a potential lack of a commercially viable enteric 
fever–only product after the research and development phase.
he roll-out of TCV in Asia and Africa means that we are 
entering a new period of enteric fever control. If TCV works as 
predicted, it is likely to have a major impact on disease burden 
and transmission of S. Typhi, creating a platform for potential 
elimination. However, we cannot aford to become complacent as 
many challenges still exist and we are now in a race against time. 
Multidrug-resistant strains are commonplace in sub-Saharan 
Africa and Asia and extensively drug-resistant variants have 
emerged in Pakistan, requiring updated management strategies. 
here also may be political complications in delivering TCV in 
all locations, and the vaccine does not protect against S. Paratyphi 
A or other forms of invasive Salmonella. he lack of a standard-
ized easy-to-use diagnostic test as an alternative, or in addition, 
to blood culture, has restricted and will greatly limit our ability 
to control enteric fever more quickly; which could have major 
repercussions in containing the efects of antimicrobial resistance 
and ultimately in reaching the goal of disease elimination.
he typhoid (enteric fever) ield has unfortunately missed 
a prime opportunity to develop and release a diagnostic tool 
alongside the introduction of new vaccines. A potential conse-
quence of this oversight is the return of the same issues that have 
hindered vaccine introduction in the past, namely an inability 
to accurately assess disease burden and measure long-term vac-
cine efectiveness. We ignore the need for new tools (alterna-
tive vaccines, diagnostics, and treatments) for enteric fever at 
our peril and we reiterate the need for a sustained ield-wide 
push to efectively diagnose, control, and eliminate the disease 
in endemic areas.
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